Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2014

View Archived Issues

Alteration of endothelial gene methylation patterns underlies atherosclerotic damage

Preclinical data on novel anti-human CCR9 MAb for leukemia

Covance to conduct phase I/II study of AM-1030 in atopic dermatitis

Amgen reports results from second phase III trial of AMG-416 in SHPT

Novel missense mutation in AR gene responsible for CAIS symptoms

Novartis invests in Gamida Cell

Positive phase III results seen with ceftazidime-avibactam in intra-abdominal infections

Hyaluronidse-2 as potential new marker for platelet activation and IBD

MediciNova discloses results from phase IIa study of ibudilast in opioid dependence

Globavir aims to launch combination of approved drugs for Ebola virus infection during 2014

GlaxoSmithKline describes progress on HCV NS5A Inhibitors

New CETP inhibitors patented by Chong Kun Dang Holdings

Acetylon Pharmaceuticals patents novel HD3 inhibitors

U.S. and Japanese group disclose new FIXa inhibitors

Chinese researchers synthesize new ALK inhibitors

Amakem divulges novel ROCK inhibitors

Cannabis Technologies developing CTI-091 for arthritis and joint disease

Mount Tam Biotechnologies licenses lupus candidate from Buck Institute

Phylogica to provide drug discovery services to Genentech

Evotec to provide compound management for Medicines for MMV's drug discovery initiatives

Altor BioScience receives NCI grant to support bladder cancer trial

FDA approves IND for ViaCyte's stem cell therapy for type 1 diabetes

FDA approves Genzyme's eliglustat for Type 1 Gaucher disease

Clinigen Group acquires Ethyol from AstraZeneca

Boehringer Ingelheim files NDA for fixed-dose combination of tiotropium and olodaterol for COPD

Janssen launches tapentadol for cancer pain in Japan

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...